Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

Do you reduce the dose of hydroxychloroquine in patients with skin graying if they are not particularly bothered by this side effect?

1
3 Answers

Mednet Member
Mednet Member
Rheumatology · Stanford University

I wouldn't if they're not bothered, but I would think to look into their HCQ blood levels... we know that certain doses of HCQ are more effective in controlling disease activity than others, and that of course, higher levels may be associated with adverse effects, not just in the skin.

Do you screen for interstitial lung disease in patients with newly diagnosed polymyositis or dermatomyositis in the absence of respiratory symptoms?

7
5 Answers

Mednet Member
Mednet Member
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth)

I do screen all newly diagnosed IIM patients with PFTs and chest CT. This has a double purpose: establishing a baseline of lung function and, screening for lung cancer. While the patient might not have lung symptoms on presentation, respiratory involvement can manifest later on the course of the d...

If methotrexate is contraindicated or not tolerated, what systemic treatments do you use for generalized morphea?

1
2 Answers

Mednet Member
Mednet Member
Rheumatology · Essentia Health Fargo

I have, in the past, used Azathioprine with partial benefit. There is no definitive treatment for Morphea. I suppose other DMARDs can be tried as well.

How do you approach an isolated positive anti-Scl-70 antibody in a patient with no symptoms or exam findings suggestive of systemic sclerosis?

1
1 Answers

Mednet Member
Mednet Member
Rheumatology · The University of Texas Health Science Center at Houston (UTHealth Houston)

We see this often in the clinic, and it is usually a false-positive test. False-positive anti-topoisomerase I (Scl-70) results frequently occur with commercial immunoassays (ELISA/Multiplex), often leading to misdiagnosis of systemic sclerosis. In our practice, we repeat the test using immunodiffusi...

What minimum clinical features or risk factors drive you to obtain a baseline HRCT in a patient with RA or Sjogren's disease?

2 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington

Overall, about 10% of RA patients will develop clinically significant ILD, as will 20% of those with SjD. Those are a significant number of people, and ILD should be on our radar as clinicians. Knowledge of risk factors for ILD can help us focus on people most likely to be affected. Several risk fac...

Do you recommend maintaining the same monitoring interval of PFTs every 3–6 months with HRCT as indicated for patients with anti-MDA5 dermatomyositis, or do you recommend closer surveillance in this group?

3 Answers

Mednet Member
Mednet Member
Rheumatology · University of Pittsburgh

Closer surveillance may be needed at diagnosis of ILD in anti-MDA5 DM at every 3 months for 1st year. But typically, in my experience, patients' symptoms progress faster than every 3 months, so rapidly progressive ILD is diagnosed clinically.

How often are you repeating screening PFTs in patients with SARDs who have 3 or more years of normal or stable PFTs?

4 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington

The answer to this question is complex and needs to be tailored to the individual patient’s risk for ILD and the particular SARD.Approximately 30-40% of patients with systemic sclerosis (SSc) will develop ILD, typically within the first 5 years after the first non-Raynaud’s manifestation and rarely ...

Which serologic tests are most helpful when evaluating for suspected drug-induced lupus?

2
2 Answers

Mednet Member
Mednet Member
Dermatology · Stanford University School of Medicine

If I suspect drug-induced lupus, I typically order the following laboratory testing: ANA/IFA Anti-histone antibody, usually positive in drug-induced lupus Anti-Ro antibody, usually positive in drug-induced subacute cutaneous lupus Anti-dsDNA, usually negative in drug-induced lupus vs positive in id...

How do you optimize retinopathy screening schedules for patients on hydroxychloroquine while also prioritizing cost-effectiveness?

3
8 Answers

Mednet Member
Mednet Member
Rheumatology · Uniformed Services University of the Health Sciences (USUHS)

I'll approach this from the cost-effectiveness standpoint as I agree with Drs. @Dr. First Last and @Dr. First Last on their excellent points.Patients with SLE have remarkably high costs when you add up copays, medications, imaging studies, travel, missing work, etc. Anything we can do to help reduce...

Before re-challenging a patient with ICI after grade 1-2 pneumonitis, do you re-image to confirm resolution of pneumonitis?

1 Answers

Mednet Member
Mednet Member
Medical Oncology · Johns Hopkins University School of Medicine

Grade 1 pneumonitis is defined as confined to one lobe of the lung or <25% of the total lung parenchyma, while grade 2 pneumonitis is defined as involving more than one lobe of the lung or 25-50% of the lung parenchyma. Grade 1 pneumonitis is typically an incidental finding on CT in an asymptomatic ...